Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

15. mai 2026 oppdatert av: Andreas Habberstad, Oslo University Hospital

Prospective Diagnostic Accuracy Study Comparing CT and MRI (VI-RADS) for Local Staging of Newly Diagnosed Bladder Cancer

This prospective diagnostic accuracy study compares computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for local staging of newly diagnosed bladder cancer. All participants undergo both imaging modalities prior to transurethral resection of the bladder tumor (TURBT) or cystectomy. Histopathology serves as the reference standard.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Accurate local staging is crucial for distinguishing non-muscle-invasive from muscle-invasive bladder cancer and guiding treatment decisions. While CT is widely used in clinical practice, MRI with VI-RADS has demonstrated higher diagnostic performance in previous retrospective and meta-analytic studies. However, prospective paired comparisons in the same patients are limited.

In this single-center prospective study, newly diagnosed bladder cancer patients undergo cystoscopy, contrast-enhanced CT, and multiparametric MRI prior to definitive histopathological sampling. Two radiologists independently assess imaging in a blinded research setting. Diagnostic performance of MRI and CT is compared using paired statistical analyses, with additional evaluation of interobserver agreement and tumor characteristics.

Studietype

Observasjonsmessig

Registrering (Antatt)

150

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Navn: Study Coordinator, Department of Urology
Telefonnummer: +47 22 89 40 00
E-post: postmottak@ous-hf.no

Studiesteder

Norge
- - Oslo, Norge
    - Rekruttering
    - Oslo University Hospital
    - Ta kontakt med:
      
      Study Coordinator, Department of Urology
      
      Telefonnummer: +47 22 89 40 00
      
      E-post: postmottak@ous-hf.no
    - Hovedetterforsker:
      
      Andreas Habberstad, MD, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Voksen
Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

The study population consists of adult patients with newly diagnosed bladder cancer identified on cystoscopy at a tertiary referral hospital. Eligible participants are patients planned for transurethral resection of the bladder tumor (TURBT) and/or cystectomy as part of standard clinical care, and who are able to undergo both contrast-enhanced computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) prior to definitive histopathological assessment.

Patients are included irrespective of tumor stage or grade at presentation, provided that imaging is performed within the defined preoperative diagnostic pathway. Patients with prior bladder cancer treatment or contraindications to imaging are excluded.

Beskrivelse

Inclusion Criteria:

Age ≥ 18 years
Newly diagnosed bladder cancer on cystoscopy
Planned TURBT or cystectomy within 6 weeks
Eligible for both CT and MRI within 6 weeks
Written informed consent provided

Exclusion Criteria:

Contraindications to MRI or iodinated contrast media
Prior treatment for bladder cancer
Pregnancy
Non-malignant bladder lesions
Tumors located in bladder diverticula

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Antall grupper / kohorter

Kohorter og intervensjoner

Gruppe / Kohort
Imaging Comparison Group All participants undergo contrast-enhanced CT and multiparametric MRI (VI-RADS) as part of routine diagnostic work-up prior to transurethral resection of the bladder tumor or cystectomy. Imaging findings are compared with histopathology for assessment of diagnostic accuracy.

Hva måler studien?

Primære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Diagnostic Accuracy for Detection of Muscle-Invasive Bladder Cancer (≥T2) Tidsramme: From imaging to final histopathological reference standard (up to 12 months)	The primary outcome is the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) compared with contrast-enhanced computed tomography (CT) for the detection of muscle-invasive bladder cancer (pathological stage ≥T2). Sensitivity and specificity will be calculated using histopathology from transurethral resection of the bladder tumor, re-TURBT, and/or cystectomy as the reference standard.	From imaging to final histopathological reference standard (up to 12 months)

Sekundære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Positive and Negative Predictive Values Tidsramme: From imaging to final histopathological reference standard (up to 12 months)	Positive predictive value (PPV) and negative predictive value (NPV) of MRI (VI-RADS) and CT for detection of muscle-invasive bladder cancer (≥T2), calculated using histopathology as the reference standard.	From imaging to final histopathological reference standard (up to 12 months)
Interobserver Agreement for MRI and CT Tumor Staging Tidsramme: During blinded image evaluation following imaging acquisition	Interobserver agreement between two independent radiologists for MRI VI-RADS scoring and CT-based T-stage assessment, quantified using weighted kappa statistics in a blinded research reading setting.	During blinded image evaluation following imaging acquisition
Proportion of correctly classified Tumor T-stage (Ta-T4) by MRI and CT Tidsramme: From imaging to final histopathological reference standard (up to 12 months)	Proportion of correctly classified tumor T-stage (Ta-T4) by MRI and CT compared with histopathological staging from TURBT and/or cystectomy.	From imaging to final histopathological reference standard (up to 12 months)
Diagnostic accuracy of MRI and CT for detection of muscle-invasive bladder cancer within tumor subgroups Tidsramme: From imaging to final histopathological reference standard (up to 12 months)	Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of MRI and CT for detection of muscle-invasive bladder cancer, assessed within predefined tumor subgroups (tumor size, morphology, tumor location and multiplicity), using histopathology as the reference standard.	From imaging to final histopathological reference standard (up to 12 months)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Oslo University Hospital

Etterforskere

Hovedetterforsker: Andreas Habberstad, MD, PhD, Oslo University Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. april 2026

Primær fullføring (Antatt)

30. april 2028

Studiet fullført (Antatt)

31. oktober 2028

Datoer for studieregistrering

Først innsendt

9. mai 2026

Først innsendt som oppfylte QC-kriteriene

15. mai 2026

Først lagt ut (Faktiske)

22. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)